The world is witnessing a groundbreaking development in the fight against Ebola, a deadly virus that has plagued Africa for decades. Professor Yasutoshi Kido and his team at Osaka Metropolitan University (OMU) have developed a revolutionary battery-powered device capable of detecting the Bundibugyo Ebola virus in just 30 minutes. This rapid diagnostic system, named GenPad, is a game-changer in the field of infectious disease control, especially in regions with limited medical resources. The device's ability to provide quick and accurate results is a significant step forward in the battle against Ebola, a virus that has caused numerous outbreaks with devastating consequences.
The development of GenPad is a testament to the power of international collaboration and rapid response in the face of a public health emergency. The project, funded by the Global Health Innovative Technology Fund (GHIT Fund), was initiated in response to the World Health Organization's (WHO) declaration of a Public Health Emergency of International Concern (PHEIC) in May 2026. This declaration highlighted the urgent need for rapid and accurate testing in affected areas, where specimen transport, power supply, and testing personnel are often limited.
One of the key challenges in diagnosing Ebola virus disease caused by Bundibugyo virus (BDBV) is the need for highly sensitive and simple testing technologies that can be deployed quickly near outbreak sites. BDBV is distinct from the more well-known Ebola virus (EBOV), and existing vaccines and diagnostic systems targeting EBOV may not be directly applicable to BDBV. Therefore, the development of a reliable testing system that can detect and differentiate BDBV is crucial.
The GenPad smart BDBV portable rapid diagnostic system utilizes K.K. DNAFORM's SmartAmp isothermal PCR technology, which enables the detection of BDBV in just 30 minutes. The system is designed to be portable, battery-powered, and capable of performing eight tests on a single charge. This makes it ideal for use in remote and resource-limited settings, where traditional laboratory facilities may not be available.
In initial laboratory testing, GenPad met the target performance criteria, including a limit of detection (LOD) of ≤200 copies per cartridge and no cross-reactivity against a panel of 86 microbial species. The system's portability and ease of use are further enhanced by its fully sealed cartridges, which simplify sample handling and reduce exposure risk. Multiple devices can be clustered together to support simultaneous testing of multiple samples, making it an efficient and effective tool for outbreak response.
The development of GenPad is a result of a collaborative effort between OMU, K.K. DNAFORM, the National Institute for Biomedical Research (INRB) of the Democratic Republic of the Congo, and the Japanese government. The project aligns with the '100-Day Mission' initiative, which aims to develop and deploy diagnostics, therapeutics, and vaccines within 100 days of identifying a new infectious disease threat. This rapid response framework has allowed the team to achieve significant milestones in a short period.
The research behind GenPad has a broader context, as OMU has been at the forefront of combating emerging infectious diseases. Since 2020, OMU has received support from the Japan Agency for Medical Research and Development's (AMED's) 'Center for Translational and Effectiveness Research in the Democratic Republic of the Congo' project, which has fostered a long-term collaborative research framework with INRB. This partnership has not only strengthened research infrastructure but has also contributed to capacity building through joint training of researchers and students.
Furthermore, OMU's collaboration with INRB extends to other emerging infectious diseases, such as mpox, which was declared a PHEIC in 2022 and 2024. The development of portable nucleic acid testing platforms for mpox, supported by AMED, has further enhanced OMU's capabilities in rapid response to infectious disease threats. K.K. DNAFORM's technology, developed with the Acquisition, Technology & Logistics Agency's Security Technology Research Promotion Program, has played a pivotal role in the rapid development of GenPad.
Looking ahead, the research team plans to validate and develop the GenPad system in phases. This includes performance validation using mock samples, clinical performance validation using clinical samples in the Democratic Republic of the Congo, and the development of a multiplex version capable of differentiating BDBV, EBOV, and SUDV within a single cartridge. The team aims to establish a BDBV-specific test to meet current urgent needs while also developing a highly versatile testing platform for future Ebola virus disease outbreaks.
In conclusion, the development of the GenPad smart BDBV portable rapid diagnostic system is a significant milestone in the fight against Ebola. It showcases the power of international collaboration, rapid response, and innovative technology in addressing public health emergencies. As the world continues to grapple with infectious diseases, such as Ebola and mpox, the development of rapid and accurate diagnostic tools like GenPad is essential to saving lives and preventing the spread of these deadly viruses.
